Payment overview · 2025
General Payments
$200.36
6 reported records · 4 companies
Healthcare provider profile · identity verified
Jason Knighton, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · POCATELLO, ID · NPI 1285199869
Verified facts
What the public records show
CMS Open Payments records show Jason Knighton, NP-C received $200.36 in general payments during 2025 across 6 reported records.
MIMEDX Group, Inc. accounted for 48.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $96.75 | 48.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.05 | 32.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.27 | 11.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.29 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.36 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.05 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 323 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 41 |
| Furosemide | Furosemide | 269 | 48 |
| Lisinopril | Lisinopril | 264 | 43 |
| Omeprazole | Omeprazole | 264 | 36 |
| Gabapentin | Gabapentin | 254 | 38 |
| Potassium Chloride | Potassium Chloride | 249 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 192 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 182 | 20 |
| Eliquis | Apixaban | 172 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 24 |
| Metformin Hcl | Metformin Hcl | 151 | 23 |
| Trazodone Hcl | Trazodone Hcl | 138 | 25 |
| Famotidine | Famotidine | 134 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 25 |
| Sertraline Hcl | Sertraline Hcl | 131 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 14 |
| Carvedilol | Carvedilol | 113 | 19 |
| Losartan Potassium | Losartan Potassium | 113 | 19 |
| Donepezil Hcl | Donepezil Hcl | 112 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 11 |
| Neomycin-Polymyxin B | Neomycin Sulf/Polymyxin B Sulf | 90 | suppressed |
| Spironolactone | Spironolactone | 88 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 86 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 13 |
| Montelukast Sodium | Montelukast Sodium | 77 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | suppressed |
| Clonazepam | Clonazepam | 75 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 21 |
| Aripiprazole | Aripiprazole | 71 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 32 |
| Tramadol Hcl | Tramadol Hcl | 70 | 16 |
| Propranolol Hcl | Propranolol Hcl | 69 | suppressed |
| Mirtazapine | Mirtazapine | 68 | suppressed |
| Nystatin | Nystatin | 68 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 13 |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Allopurinol | Allopurinol | 57 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | suppressed |
| Lorazepam | Lorazepam | 55 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 54 | suppressed |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | suppressed |
| Meloxicam | Meloxicam | 49 | suppressed |
| Cefdinir | Cefdinir | 48 | 34 |
| Cephalexin | Cephalexin | 48 | 20 |
| Risperidone | Risperidone | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 43 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Vraylar | Cariprazine Hcl | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Simvastatin | Simvastatin | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Prednisone | Prednisone | 32 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 16 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 13 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 15 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Linzess | Linaclotide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.36 · 6 records | MIMEDX Group, Inc. | MOUNJARO, VRAYLAR, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error